Charlotte Figi, an eight-year-old girl from Colorado with Dravet syndrome, a rare and debilitating form of epilepsy, came into the public eye in 2013 when news broke that medical marijuana was able to do what other drugs could not: dramatically reduce her seizures. Now, new scientific research provides evidence that cannabis may be an effective treatment for a third of epilepsy patients who, like Charlotte, have a treatment-resistant form of the disease.
LATEST EFGC NEWS
Children with epilepsy should have a plan in place at school for how best to respond to medical emergencies. The American Academy of Pediatrics (AAP) has released guidance suggesting prescribing providers, families, and schools collaborate develop such plans detailing the use of seizure rescue medications.
The condition doesn’t play favorites: People are diagnosed with epilepsy at any age and it can be triggered by a wide range of factors. The Chicago Wolves are determined to broaden the conversation of this condition and to raise funds to cure it.
The hospital pharmacist slid three bottles of pills across the counter, gave my wife a form to sign, and reminded her that this was not the corner drugstore. The pharmacy knew how many pills had been dispensed, he said; it would know how many had been consumed; and it would expect her to return the unused pills before she left the country. The pharmacist made it clear that he was not only in touch with our doctor but with the company supplying the medication. They would know if she broke the rules.
On September 24, 2015, the Illinois State Senate was able to pass SB 2046, which gives the governor authority to resume payments to health and human services organizations, including the Epilepsy Foundation of Greater Chicago. As Illinois legislators and Governor Rauner continue to battle over the state budget, this is clearly a step in the right direction for non-profit organizations who rely so heavily on government funding–it will help prevent the shutdown of vital services provided by the Epilepsy of Greater Chicago to the 130,000 people with epilepsy living within the greater Chicagoland area.
PhRMA and the Epilepsy Foundation report more than 400 medicines in development to treat neurological disorders
America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis (MS) and Parkinson’s disease. As highlighted in a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Epilepsy Foundation, scientists around the globe are collaborating to find new or more effective treatments for patients with these complex disorders that attack the nervous system.
Eisai Announces FDA Approval of New Indication for Primary Generalized Tonic-Clonic (PGTC) Seizures in Patients with Epilepsy Age 12 and Older
Eisai Inc. announced on June 22nd, 2015, that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII for adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures in patients age 12 and older. FYCOMPA, the first and only FDA-approved non-competitive AMPA receptor antagonist, was initially approved in October 2012 as adjunctive treatment for partial-onset seizures, with or without secondarily generalized seizures, in patients with epilepsy age 12 and older.